Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference
Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit and follow Oruka on LinkedIn.MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced participation and a fireside chat at Piper Sandler's 36th Annual Healthcare Conference:
加利福尼亚州门洛公园，2024年11月19日（GLOBE NEWSWIRE）——生物技术公司Oruka Therapeutics, Inc.（“Oruka”）（纳斯达克股票代码：ORKA）是一家开发旨在为包括斑块状牛皮癣在内的慢性皮肤病治疗设定新标准的生物制剂的生物技术公司，今天宣布参加派珀·桑德勒的第36届年度医疗保健会议并在炉边谈话：
Date: Tuesday, December 3rd, 2024
Time: 3:00PM ET
日期：2024 年 12 月 3 日星期二
时间：美国东部时间下午 3:00
About Oruka Therapeutics
关于 Oruka 疗法
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit and follow Oruka on LinkedIn.
Oruka Therapeutics正在开发新的生物制剂，旨在为慢性皮肤病的治疗设定新的标准。Oruka的使命是通过实现较高的完全清除率，每年少给药一两次，为患有斑块状牛皮癣等慢性皮肤病的患者提供尽可能大的摆脱病情的机会。Oruka正在推进由Paragon Therapeutics设计的潜在同类最佳抗体的专有产品组合，针对斑块状银屑病和其他皮肤病和炎症性疾病的核心机制。欲了解更多信息，请在领英上访问并关注 Oruka。
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
投资者联系人：
艾伦·拉达
(650) -606-7911
alan.lada@orukatx.com
